Key Takeaways
- GLP-1 users lose 39–40% of weight as lean mass (STEP-1 trial) — companion supplements aim to close that gap through muscle preservation, nutrient repletion, and GI support.
- The GLP-1 companion supplement market reached $2.2 billion in 2026, growing at 12–14% CAGR, driven by the 6+ million Americans now on semaglutide or tirzepatide.
- The 7 trending supplements: creatine monohydrate, HMB, high-protein formulas, probiotics/fibre, electrolytes, vitamin D3, and collagen peptides — each addresses a specific, documented deficit.
- Evidence quality varies: creatine and protein have strong general evidence for muscle preservation during caloric restriction, but direct RCTs in GLP-1 populations are still limited for most supplements.
- The minimum effective stack on a budget: whey protein, electrolytes, vitamin D3, and creatine — total cost under $2/day.
Six million Americans are now taking GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound). They eat roughly 20% fewer calories per day, lose 15–22% of body weight over 68 weeks, and — as the STEP-1 and SURMOUNT-1 trials documented — shed a significant fraction of lean mass in the process. The supplement industry noticed. In the space of 18 months, “GLP-1 companion” has become its own product category, with brands from Thorne to NatureMade launching dedicated stacks. The question isn't whether this market is real — at $2.2 billion and growing at nearly 12% annually, it clearly is. The question is which of these supplements actually have evidence behind them.
Why GLP-1 Users Need Companion Supplements
GLP-1 receptor agonists work by mimicking the incretin hormone GLP-1, which slows gastric emptying, reduces appetite via hypothalamic signalling, and enhances insulin secretion. The downstream effect is that users eat substantially less — and when you eat less, you absorb less of everything: protein, vitamins, minerals, fibre.
Three categories of deficit emerge consistently in the literature:
Lean Mass Loss
Caloric restriction without adequate protein and resistance training leads to disproportionate muscle loss. In STEP-1, 39–40% of weight lost was lean mass — roughly 6.9 kg out of 15.3 kg total (Wilding et al., 2021, NEJM).
Micronutrient Depletion
Reduced food intake and slowed gastric emptying impair absorption of fat-soluble vitamins. GLP-1 users show 49% higher risk of vitamin D deficiency compared to users of other diabetes medications (Remedys Nutrition, 2026 analysis). B12, iron, and magnesium gaps are also documented.
GI Disruption
Nausea affects 20–44% of semaglutide users at the 2.4mg dose; constipation persists in 24% (Friedrichsen et al., 2021, Obesity). These side effects reduce dietary diversity further and create a feedback loop of under-nutrition.
What this means for you
If you're on a GLP-1 medication, supplementation isn't optional wellness — it's compensating for a measurable reduction in nutrient intake. The question is which supplements actually address documented deficits versus which are marketing dressed up as science.
The Muscle Loss Problem: What the Trials Actually Show
The lean mass conversation around GLP-1 drugs is often oversimplified. Some advocates dismiss it — “you lose muscle whenever you lose weight” — while critics treat it as a fatal flaw. The data sits between these positions.
Semaglutide 2.4mg produced 14.9% body weight loss over 68 weeks. DEXA sub-study showed lean mass reduction of 6.92 kg (placebo-corrected: −5.44 kg), representing 39–40% of total weight lost.
Tirzepatide 15mg produced 22.5% weight loss. Lean mass fraction lost was comparable at 33–40% depending on dose tier. The higher absolute weight loss meant more lean mass was lost in absolute terms.
This study specifically measures semaglutide's impact on fat mass, lean mass, and muscle function using DEXA and grip strength. Early data suggests that resistance training substantially attenuates lean mass loss — reducing the lean mass fraction from ~40% to ~20% of total weight lost.
The critical nuance: lean mass loss during GLP-1 therapy is not inevitable at the levels seen in the headline trials. Resistance training is the primary intervention. Supplements — particularly creatine, HMB, and adequate protein — are the secondary line of defence. Neither replaces the other.
The 7 GLP-1 Companion Supplements Trending in 2026
We evaluated each supplement on three criteria: (1) strength of evidence for the specific claim being made, (2) relevance to documented GLP-1 side effects or deficits, and (3) cost-effectiveness. Here's the honest assessment.
| Supplement | Primary Claim | Evidence | Cost/day |
|---|---|---|---|
| Creatine monohydrate | Lean mass preservation | Strong* | $0.05–0.10 |
| HMB | Anti-catabolic | Moderate | $0.50–1.00 |
| Whey / protein | Muscle protein synthesis | Strong | $0.80–1.50 |
| Probiotics + fibre | GI side effect relief | Moderate | $0.30–1.00 |
| Electrolytes + Mg | Hydration / deficiency | Strong | $0.15–0.40 |
| Vitamin D3 | Deficiency prevention | Strong | $0.05–0.10 |
| Collagen peptides | Skin / lean mass | Limited | $0.50–1.20 |
* “Strong” = robust RCT evidence for the general claim; not all have been tested directly in GLP-1 populations.
1. Creatine Monohydrate — The Strongest Case
Creatine is the single most studied sports supplement in existence, with over 500 peer-reviewed papers supporting its efficacy for lean mass and strength. Its relevance to GLP-1 users is straightforward: it preserves muscle during caloric restriction.
Argues creatine is a “promising adjunct strategy” for GLP-1 users based on three mechanisms: enhanced phosphocreatine resynthesis during resistance training, satellite cell activation for muscle repair, and reduced myostatin expression. The paper calls for direct RCTs in GLP-1 populations.
In older adults undergoing caloric restriction, creatine supplementation (5g/day) combined with resistance training consistently preserves more lean mass than resistance training alone. A meta-analysis by Chilibeck et al. (2017, Journal of the International Society of Sports Nutrition) across 22 RCTs found creatine increased lean tissue mass by an average of 1.37 kg compared to placebo during resistance training programmes.
Dose
3–5g per day
Monohydrate form. No loading phase needed.
Cost
~$0.05–0.10/day
Among the cheapest effective supplements available.
Limitation:No large RCT has tested creatine specifically in a GLP-1 cohort. The evidence is extrapolated from caloric restriction and aging studies. Given creatine's safety profile (no clinically meaningful adverse effects in healthy adults at 3–5g/day per ISSN position stand) and cost, the risk-benefit calculation strongly favours use.
2. HMB (β-Hydroxy β-Methylbutyrate) — The Anti-Catabolic
HMB is a metabolite of leucine that acts on the ubiquitin-proteasome pathway — the primary mechanism through which the body breaks down muscle protein. During caloric restriction, this pathway becomes hyperactive. HMB dampens it.
3g/day HMB during 4 weeks of resistance training increased lean body mass and reduced body fat percentage more than placebo. HMB users achieved similar fat-loss totals as controls but retained approximately twice the lean mass.
The International Society of Sports Nutrition position stand recommends 3g/day of HMB, noting it “can be used to enhance recovery by attenuating exercise-induced skeletal muscle damage in trained and untrained populations” (Wilson et al., 2013, J Int Soc Sports Nutr). For GLP-1 users, the anti-catabolic mechanism is the key draw — HMB isn't primarily about building muscle, it's about slowing the rate at which you lose it during a caloric deficit.
Limitation:Meta-analyses are mixed. Rowlands & Thomson (2009) found modest effects that were strongest in untrained individuals and during the first 2 weeks of training. The HMB-specific evidence in weight-loss populations is smaller-scale than creatine's. At $0.50–1.00/day, it's a reasonable add-on if budget allows but not the first priority.
3. High-Protein Supplements — The Non-Negotiable
This is the least controversial recommendation on the list. When you eat 20% fewer calories, protein intake drops proportionally unless you actively compensate. The Obesity Medicine Association and multiple clinical guidelines now recommend GLP-1 users target 1.2–1.6 g/kg of target body weight per day — roughly double the standard RDA of 0.8 g/kg.
Why protein supplementation matters more on GLP-1s
A 75kg person targeting 1.4 g/kg needs 105g of protein daily. If they're eating 1,600 calories (a typical intake on semaglutide 2.4mg), that means 26% of calories must come from protein — achievable, but requires deliberate planning or supplementation. Most users fall short without a protein supplement.
Whey protein isolate remains the gold standard for muscle protein synthesis due to its leucine content (10–12% by weight) and rapid absorption kinetics. For GLP-1 users with GI sensitivity, whey isolate is preferable to concentrate because the lactose has been largely removed. Plant-based blends (pea + rice) are a viable alternative for those who are dairy-intolerant — the amino acid profile is slightly inferior but the difference is clinically marginal when total daily intake is adequate.
What this means for you
Aim for 25–40g of protein per meal across 3–4 meals. If appetite suppression makes solid food difficult, a whey shake between meals is the simplest intervention. Distribute protein evenly — a single 80g protein meal is less effective for MPS than three 27g servings.
4. Probiotics & Fibre — Managing the GI Fallout
Gastrointestinal side effects are the most common reason people discontinue GLP-1 therapy. Nausea affects 20–44% of semaglutide users; constipation persists in roughly 24% even after titration (Friedrichsen et al., 2021, Obesity). The companion supplement industry has responded with GLP-1-specific probiotic formulations — and the rationale is actually grounded in biology, not just marketing.
The gut microbiome produces short-chain fatty acids and secondary bile acids that stimulate endogenous GLP-1 secretion. Microbiome composition also appears to influence inter-individual response to GLP-1 therapy. A clinical trial currently underway (NCT07130396) is testing UltraFlora Balance Probiotic combined with a multivitamin specifically in GLP-1 users — the first trial designed to measure probiotic impact on GI tolerability during GLP-1 treatment.
Probiotics — What to Look For
Multi-strain: Lactobacillus + Bifidobacterium species
10+ billion CFU per dose
Shelf-stable formulation (no cold chain needed)
Enteric coating for GI survival
Fibre — The Constipation Fix
Psyllium husk: 5–10g/day, start at 5g
Titrate slowly — rapid fibre increase worsens bloating
Take with ≥250ml water per 5g dose
Separate from GLP-1 injection by 1+ hour
Limitation: Probiotic evidence for GI relief in general populations is moderate; evidence specifically in GLP-1 populations is preliminary. The NCT07130396 trial will provide the first rigorous data. In the meantime, multi-strain probiotics combined with psyllium fibre is the approach most commonly recommended by GI specialists treating GLP-1 users.
5. Electrolytes & Magnesium — The Silent Deficit
Reduced food intake means reduced electrolyte intake. Add in the nausea and vomiting that affect a significant minority of users, and the dehydration risk compounds. Magnesium deserves special mention: it's involved in over 300 enzymatic reactions, and subclinical deficiency is already present in an estimated 50% of Americans before they start a GLP-1 drug (Rosanoff et al., 2012, Nutrition Reviews).
GLP-1 companion formulas are increasingly built around magnesium citrate, which offers superior bioavailability compared to magnesium oxide (the cheapest and most common form in multivitamins). A 2026 industry analysis by Green Jeeva noted that magnesium citrate is now the second-most-requested ingredient in GLP-1 companion formulations, behind only protein.
Minimum daily electrolytes
Sodium: 1,500–2,300mg
Potassium: 2,600–3,400mg
Magnesium: 310–420mg
Best forms for absorption
Mg citrate or Mg glycinate
Avoid Mg oxide (4% bioavailability)
Glycinate preferred if GI-sensitive
6. Vitamin D3 — The Absorption Problem
Vitamin D is fat-soluble. GLP-1 drugs slow gastric emptying and reduce dietary fat intake — both of which impair fat-soluble vitamin absorption. A 2026 analysis found GLP-1 users face a 49% higher risk of vitamin D deficiency compared to users of other diabetes medications, even after controlling for baseline vitamin D status and sun exposure.
This matters beyond bone health. Vitamin D receptors are expressed in skeletal muscle, and deficiency is independently associated with reduced muscle strength and increased fall risk — a 2014 meta-analysis by Beaudart et al. (Journal of Clinical Endocrinology & Metabolism) found that vitamin D supplementation improved lower limb muscle strength in deficient individuals. For GLP-1 users already at risk of lean mass loss, vitamin D deficiency compounds the problem.
Recommended dose
2,000–4,000 IU/day (D3, not D2)
Take with a fat-containing meal to improve absorption.
Monitoring
Check 25(OH)D levels every 6 months
Target: 40–60 ng/mL (100–150 nmol/L).
7. Collagen Peptides — The Skin Elasticity Play
Rapid weight loss — particularly the 15–22% body weight reductions seen with semaglutide and tirzepatide — leaves excess skin. Collagen peptide supplements have surged in the GLP-1 companion market on the promise of supporting skin elasticity and connective tissue during this transition. The evidence is real but limited.
15g daily collagen peptides combined with resistance training increased fat-free mass and decreased fat mass over 12 weeks compared to placebo + resistance training. The collagen group also showed improved body composition ratios.
For skin elasticity specifically, a 2019 systematic review by de Miranda et al. (International Journal of Dermatology) found that 2.5–10g/day of collagen peptides improved skin hydration, elasticity, and wrinkle depth in 11 RCTs. However, these studies were conducted in general populations, not in individuals undergoing rapid weight loss.
Honest assessment:Collagen provides protein (10–20g per serving) but has an incomplete amino acid profile — low in leucine, the primary driver of muscle protein synthesis. It should supplement, not replace, whey or complete protein sources. For skin elasticity during rapid weight loss, the evidence is plausible but not proven in GLP-1 populations specifically. It's the weakest recommendation on this list — reasonable to try, but manage expectations.